A review of AbobotulinumtoxinA (Dysport).
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23515194.
- Also identified by DOI 10.1177/1090820X12474632.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.
Medical subject headings
- Botulinum Toxins, Type A
- Neurotransmitter Agents
- Rejuvenation